-Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovativ...
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical ...
“We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bemped...
Gilles Besin, Ph.D., CSO at Orbital: “Elegen's unique expertise in supplying...IVT-ready synthetic DNA constructs is very attractive ...
Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancr...
Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete ...
Dr. Crystal Proud, Pediatric Neurologist at Children’s Hospital of the King’s Daughters, remarked, “Our evolving understanding of...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to d...
BeiGene, Ltd. announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed...
The residual HCPs are generated by organisms used for making recombinant biopharmaceutical products. They are considered as process-related impurities. Sin...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
QIAGEN announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biote...
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...
© 2024 Biopharma Boardroom. All Rights Reserved.